Oncolytics Biotech Files Routine 6-K, Confirms 20-F Reporting
Ticker: ONCY · Form: 6-K · Filed: Feb 28, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Feb 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, compliance
TL;DR
**Oncolytics Biotech just filed a routine 6-K, confirming its foreign private issuer status and 20-F annual reporting.**
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on February 28, 2024, indicating its status as a foreign private issuer. The filing confirms the company's address as Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5, and specifies that it files annual reports under Form 20-F. This routine filing updates the public record regarding the company's reporting obligations under the Securities Exchange Act of 1934.
Why It Matters
This filing is a standard regulatory update, providing transparency on Oncolytics Biotech's compliance with SEC reporting requirements as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no new material financial or operational information, posing minimal risk.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — registrant
- February 2024 (date) — month of report
- 001-38512 (other) — Commission File Number
- Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (other) — principal executive offices address
- Form 20-F (other) — annual report filing type
- Form 6-K (other) — submission type
- Securities Exchange Act of 1934 (other) — governing act
FAQ
What type of report did Oncolytics Biotech Inc. file?
Oncolytics Biotech Inc. filed a Form 6-K, which is a Report of Foreign Private Issuer.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Under which form does Oncolytics Biotech Inc. file its annual reports?
Oncolytics Biotech Inc. indicates that it files its annual reports under Form 20-F.
What is the purpose of a Form 6-K filing for a foreign private issuer?
A Form 6-K is used by foreign private issuers to furnish the SEC with material information that is made public in their home country, distributed to shareholders, or filed with a foreign exchange, as per Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-02-28 13:09:09
Filing Documents
- form6kcagla.htm (6-K) — 18KB
- cagla.htm (EX-99.1) — 11KB
- 0001129928-24-000008.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date February 28, 2024 Kirk Look Chief Financial Officer